J&J claims a Tecvayli/Darzalex combo win
The company has seen a PFS and OS benefit in the phase 3 Majestec-3 trial.
Licensing analysis: small deals dominate
The biggest Q3 agreement was AbbVie’s $700m swoop for Glenmark's trispecific T-cell engager.
Genmab takes its Profound buy into endometrial
The Rainfol-03 trial, in second-line endometrial cancer, builds on recent early data.
AbbVie broadens its telisotuzumab conjugate push
A new phase 2/3 will enrol a broad second-line EGFR-mutant NSCLC population.
AbbVie makes a bigger bet on SEZ6
But first it will need to identify the optimal dose in first-line small-cell lung cancer.
Gilead gets into in vivo Car-T
Interius, one of the most advanced players, will cost $350m.
Columvi avoids its worst-case scenario
Roche’s drug is knocked back in second-line lymphoma, but keeps its third-line nod.
M&A analysis: signs of life emerge
Some big deals in the second quarter have raised hopes that takeouts are back.
